A RADICAL, INNOVATIVE WAY TO TREAT RESPIRATORY VIRUS
CytoAgents is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of Covid-19, influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of life threatening symptoms associated with Covid-19 and influenza and Cytokine Releasing Syndrome by modulating the natural immune response to the disease. We are committed to developing a first-in-class, best-in-class products that meet a major medical need.
EPIDEMIC: A DEVASTATING PUBLIC HEALTH THREAT
COVID-19 AND INFLUENZA
New strains and combinations of influenza strains circulate every year and the Covid-19 pandemic is shining a spotlight on our current inadequate pharmacological responses.
The cornerstone of influenza therapy is vaccination and anti-viral medications, both of which have significant limitations. Currently, there are no effective treatments to treat these respiratory symptoms associated with an average of 13M medical visits annually.
GP1681: ADDRESSING AN UNMET NEED
CytoAgents’ lead candidate, GP1681, addresses a clear unmet need and will expand the category for therapy options available for the treatment of Covid-19 and influenza, along with addressing other conditions associated with cytokine release syndrome.